Study to Evaluate the Effect of Ticagrelor Versus Placebo in Reducing Vaso-Occlusive Crises Rate in Pediatric Patients With Sickle Cell Disease. (HESTIA5)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04293172 |
|
Recruitment Status :
Withdrawn
(Study halted prematurely, prior to enrolment of first patient.)
First Posted : March 3, 2020
Last Update Posted : July 15, 2020
|
Sponsor:
AstraZeneca
Collaborator:
Iqvia Pty Ltd
Information provided by (Responsible Party):
AstraZeneca
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Study was withdrawn before participants were enrolled.
| Recruitment Status : | Withdrawn |
|---|---|
| Estimated Primary Completion Date : | October 10, 2022 |
| Estimated Study Completion Date : | October 10, 2022 |